{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-006077","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2026-08-07T12:35:15+00:00","discovered_at":"2026-08-07T12:40:00.458473+00:00","generated_at":"2026-08-07T12:40:11.386114+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xenetic Q2 2026 net loss $0.9M; royalty revenue up 12% to $0.7M","bullets":["Net loss $0.9M vs $0.7M Q2 2025; cash $6.5M at June 30, 2026 vs $7.9M at Dec 31, 2025.","Royalty revenue $0.7M, +12% YoY, from Takeda sublicense; first-half royalties ~$1.5M.","R&D expenses $0.6M (-16% YoY); G&A $1.1M (+64%) on strategic review legal costs.","ASCO data: DNase I enhanced CAR T expansion, persistence, tumor control; PeriNess study approved for LBCL.","Strategic review process ongoing; interim CEO James Parslow emphasizes disciplined capital allocation."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-006077","json":"https://secwatch.observer/filing/0001683168-26-006077.json","markdown":"https://secwatch.observer/filing/0001683168-26-006077.md","text":"https://secwatch.observer/filing/0001683168-26-006077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826006077/0001683168-26-006077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826006077/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-07T12:40:11.386114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}